BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 15044036)

  • 1. Mutagenesis at the human tachykinin NK(2) receptor to define the binding site of a novel class of antagonists.
    Meini S; Bellucci F; Catalani C; Cucchi P; Patacchini R; Rotondaro L; Altamura M; Giuliani S; Giolitti A; Maggi CA
    Eur J Pharmacol; 2004 Mar; 488(1-3):61-9. PubMed ID: 15044036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multifaceted approach to determine the antagonist molecular mechanism and interaction of ibodutant ([1-(2-phenyl-1R-[[1-(tetrahydropyran-4-ylmethyl)-piperidin-4-ylmethyl]-carbamoyl]-ethylcarbamoyl)-cyclopentyl]-amide) at the human tachykinin NK2 receptor.
    Meini S; Bellucci F; Catalani C; Cucchi P; Giolitti A; Santicioli P; Giuliani S
    J Pharmacol Exp Ther; 2009 May; 329(2):486-95. PubMed ID: 19218528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relevance of aromatic residues in transmembrane segments V to VII for binding of peptide and nonpeptide antagonists to the human tachykinin NK(2) receptor.
    Renzetti AR; Catalioto RM; Criscuoli M; Cucchi P; Ferrer C; Giolitti A; Guelfi M; Rotondaro L; Warner FJ; Maggi CA
    J Pharmacol Exp Ther; 1999 Aug; 290(2):487-95. PubMed ID: 10411554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology of an original and selective nonpeptide antagonist ligand for the human tachykinin NK2 receptor.
    Meini S; Catalani C; Bellucci F; Cucchi P; Giuliani S; Zappitelli S; Rotondaro L; Pasqui F; Guidi A; Altamura M; Giolitti A; Maggi CA
    Eur J Pharmacol; 2005 Jun; 516(2):104-11. PubMed ID: 15925360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MEN 11420 (Nepadutant), a novel glycosylated bicyclic peptide tachykinin NK2 receptor antagonist.
    Catalioto RM; Criscuoli M; Cucchi P; Giachetti A; Gianotti D; Giuliani S; Lecci A; Lippi A; Patacchini R; Quartara L; Renzetti AR; Tramontana M; Arcamone F; Maggi CA
    Br J Pharmacol; 1998 Jan; 123(1):81-91. PubMed ID: 9484857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MEN 10,627, a novel polycyclic peptide antagonist of tachykinin NK2 receptors.
    Maggi CA; Astolfi M; Giuliani S; Goso C; Manzini S; Meini S; Patacchini R; Pavone V; Pedone C; Quartara L
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1489-500. PubMed ID: 7996462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological evaluation of alpha and beta human tachykinin NK(2) receptor splice variants expressed in CHO cells.
    Bellucci F; Meini S; Catalioto RM; Catalani C; Giuliani S; Quartara L; Giolitti A; Faiella A; Rotondaro L; Candenas ML; Pinto FM; Maggi CA
    Eur J Pharmacol; 2004 Sep; 499(3):229-38. PubMed ID: 15381044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [3H][beta-Ala8]neurokinin A-(4-10): a novel, selective radioligand for the tachykinin NK2 receptor.
    Goso C; Astolfi M; Parlani M; Manzini S
    Eur J Pharmacol; 1995 Dec; 294(1):239-45. PubMed ID: 8788437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of nepadutant at tachykinin NK(2) receptors in human intestine and urinary bladder.
    Patacchini R; Giuliani S; Turini A; Navarra G; Maggi CA
    Eur J Pharmacol; 2000 Jun; 398(3):389-97. PubMed ID: 10862829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MEN15596, a novel nonpeptide tachykinin NK2 receptor antagonist.
    Cialdai C; Tramontana M; Patacchini R; Lecci A; Catalani C; Catalioto RM; Meini S; Valenti C; Altamura M; Giuliani S; Maggi CA
    Eur J Pharmacol; 2006 Nov; 549(1-3):140-8. PubMed ID: 16979621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monocyclic human tachykinin NK-2 receptor antagonists as evolution of a potent bicyclic antagonist: QSAR and site-directed mutagenesis studies.
    Giolitti A; Altamura M; Bellucci F; Giannotti D; Meini S; Patacchini R; Rotondaro L; Zappitelli S; Maggi CA
    J Med Chem; 2002 Aug; 45(16):3418-29. PubMed ID: 12139452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SCH 206272: a potent, orally active tachykinin NK(1), NK(2), and NK(3) receptor antagonist.
    Anthes JC; Chapman RW; Richard C; Eckel S; Corboz M; Hey JA; Fernandez X; Greenfeder S; McLeod R; Sehring S; Rizzo C; Crawley Y; Shih NY; Piwinski J; Reichard G; Ting P; Carruthers N; Cuss FM; Billah M; Kreutner W; Egan RW
    Eur J Pharmacol; 2002 Aug; 450(2):191-202. PubMed ID: 12206858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of a tachykinin NK(2) receptor antagonist, nepadutant, on cardiovascular and gastrointestinal function in rats and dogs.
    Giuliani S; Guelfi M; Toulouse M; Buéno L; Lecci A; Tramontana M; Criscuoli M; Maggi CA
    Eur J Pharmacol; 2001 Mar; 415(1):61-71. PubMed ID: 11245853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the antibronchoconstrictor activity of MEN 11420, a tachykinin NK2 receptor antagonist, in guinea-pigs.
    Tramontana M; Patacchini R; Giuliani S; Lippi A; Lecci A; Santicioli P; Criscuoli M; Maggi CA
    Eur J Pharmacol; 1998 Jul; 352(2-3):279-88. PubMed ID: 9716365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular determinants of peptide and nonpeptide NK-2 receptor antagonists binding sites of the human tachykinin NK-2 receptor by site-directed mutagenesis.
    Giolitti A; Cucchi P; Renzetti AR; Rotondaro L; Zappitelli S; Maggi CA
    Neuropharmacology; 2000 Jun; 39(8):1422-9. PubMed ID: 10818258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different mechanism of tachykinin NK2 receptor blockade by SR 48968 and MEN 10,627 in the guinea-pig isolated gallbladder and colon.
    Patacchini R; De Giorgio R; Giachetti A; Maggi CA
    Eur J Pharmacol; 1994 Dec; 271(1):111-9. PubMed ID: 7698194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel ligands lacking a positive charge for the delta- and mu-opioid receptors.
    Schiller PW; Berezowska I; Nguyen TM; Schmidt R; Lemieux C; Chung NN; Falcone-Hindley ML; Yao W; Liu J; Iwama S; Smith AB; Hirschmann R
    J Med Chem; 2000 Feb; 43(4):551-9. PubMed ID: 10691681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tachykinin NK(2) receptor mediates contraction and ion transport in rat colon by different mechanisms.
    Patacchini R; Cox HM; Ståhl S; Tough IR; Maggi CA
    Eur J Pharmacol; 2001 Mar; 415(2-3):277-83. PubMed ID: 11275010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological profile of the novel mammalian tachykinin, hemokinin 1.
    Bellucci F; Carini F; Catalani C; Cucchi P; Lecci A; Meini S; Patacchini R; Quartara L; Ricci R; Tramontana M; Giuliani S; Maggi CA
    Br J Pharmacol; 2002 Jan; 135(1):266-74. PubMed ID: 11786503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of YM-44781, YM-44778 and YM-49598, novel tachykinin antagonists, in a drug-induced bladder contraction model.
    Choppin A; Groke G; Bringas A; Stepan G; Dillon MP
    Pharmacology; 2002 May; 65(2):96-102. PubMed ID: 11937780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.